KẾT QUẢ SỚM XẠ TRỊ ĐIỀU BIẾN LIỀU KẾT HỢP HÓA TRỊ ĐỒNG THỜI UNG THƯ VÒM MŨI HỌNG GIAI ĐOẠN III-IVA

Abstract

Nasopharyngeal cancer (NPC) is the most common site of cancer inthe head and neck. The nasopharyn is located deeply in many nearby important organs, so the role of modern radiotherapy techniques (IMRT, VMAT, IGRT…) in combination with chemotherapy has been increasingly studied and became the standard of care. Objective: to evaluate early treatment results and some related factors of intensity modulated radiation therapy (IMRT) regimen combined with concurrent chemotherapy of nasopharyngeal cancer stage III-IVA AJCC 8^th 2017 in Nghe An Oncology Hospital. Patients and Methods: Retrospective and prospective description included 42 patients with stage III-IVA NPC (except N3 nodes metastisis group), histopathology of undifferentiated carcinoma, ECOG 0-1, from April 2019 to March 2021 at NgheAnOncology Hospital. Results: 100% of patients had enough concurrent chemoradiotherapy (CCRT) with 3 cycles of Cisplatin on days 1, 22, 43 and one cycle of adjuvant chemotherapy (ACT) with Cisplatin plus 5FU, 90,5% completed the regimen. The rates of complete response (CR) after CCRT at tumor, lymph node and both were 88,1%; 85,7%; 76,2%, respectively; the remaining patients had partial response. The rates of CR after ACT at tumor, lymphnode and both were 92,9%; 88,1%; 85,7%, respectively; the remaining patients had partial response. Conclusion: Concurrent chemoradiotherapy withIMRT was safe and effective in stage III-IVA nasopharyngreal carcinoma patients.